Results 131 to 140 of about 17,756 (247)

Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML

Blood, 2022
G. Ehninger, S. Kraus, E. Sala, S. Metzelder, V. Vučinić, W. Fiedler, M. Goebeler, J. Middeke, M. von Bonin, C. Kreissig, J. Koedam, M. Cartellieri, A. Ehninger, M. Wermke, Jonas A. Schäfer   +14 more
semanticscholar   +1 more source

Anti-CD123 ADC IMGN632 [PDF]

, 2020
openaire   +1 more source

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm. [PDF]

J Hematol Oncol
Budde LE, Del Real MM, Song J, Stiller T, Wang Y, Aribi A, Sandhu K, Nakamura R, Marcucci EC, Wu JJ, Ng K, Clark MC, Wood B, Wagner JR, Paul J, Brown CE, Stein A, Marcucci G, Blanchard MS, Palmer J, Forman SJ.   +20 more
europepmc   +1 more source

Preclinical characterization of the anti-leukemia activity of the CD123 antibody-drug conjugate, pivekimab sunirine (IMGN632)

Acute myeloid leukemia (AML) remains difficult to cure [1, 2]. Antibody-based drugs have long been pursued to improve these outcomes. While early efforts focused on CD33, there is increasing interest in CD123 as a drug target [3].
Lakshmikanthan, Sribalaji, Wu, David, Nyberg, Kyle, Zweidler McKay, Patrick A., Lunn-Halbert, Margaret C., Pettenger Willey, Camryn M., Laszlo, George S., Cole, Frances M., Li, Junyang, Kehret, Allie R., Lim, Sheryl Y. T., Walter, Roland B., Rodríguez-Arbolí, Eduardo   +12 more
core   +1 more source

Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature. [PDF]

Front Immunol
Yang F, Li D, Lei Y, Liu R, Fu Z, Ma L, Deng B, Ke X, Hu K.   +8 more
europepmc   +1 more source

Antigen-directed p53 restoration in <i>TP53</i>-mutated myeloid neoplasms: a hypothesis and theory perspective. [PDF]

Front Oncol
Medawar G, Pyle S, Baratam P, Coltoff A.
europepmc   +1 more source

Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax. [PDF]

Ann Hematol
Zhang M, Chai X, Zhang X, Lu W, Lyu H, Pu Y, Meng J, Lyu C, Zhao M.   +8 more
europepmc   +1 more source

Case Report: Blastic plasmacytoid dendritic cell neoplasm mimicking systemic lymphoma: a multidisciplinary diagnostic challenge. [PDF]

Front Med (Lausanne)
Lv B, Rong Q, Li Y, Zhang D.
europepmc   +1 more source

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study. [PDF]

J Hematol Oncol
Short NJ, Bataller A, DiNardo CD, Montalban-Bravo G, Wang SA, Wang W, Maiti A, Nguyen D, Hachem MC, Bi TM, Issa GC, Chien KS, Ohanian M, Kadia TM, Loghavi S, Karrar O, Bachireddy P, Hwang H, Huang X, Garcia-Manero G, Ravandi F.   +20 more
europepmc   +1 more source

Suggestive characteristic change of CD123⁺dendritic cells in Kikuchi-Fujimoto Disease. [PDF]

J Clin Exp Hematop
Asano S, Mori K, Yamazaki K, Sato H, Naito H, Yamada R, Komohara Y.   +6 more
europepmc   +1 more source